We develop new formulations of drugs to combat antibiotic resistance.
Antibiotic Resistance (AR)
Due to the excessive use of antibiotics in livestock and humans, bacteria can develop AR. It threatens the US with 2.8 million infections each year (CDC 2019) and a projected 10 million deaths each year by 2050 (The Welcome Trust 2014). More targeted therapies that deliver the drug on-site can better combat bacteria that currently have AR.
Clostridium Difficile infection (CDI)
C. difficile is a Gram-positive bacterium, causes diarrhea and life-threatening colitis. It is responsible for half a million incidences and about 29,000 deaths each year in the US. Resistant strains are reported in recent years with the occurrence of large breakouts. We are currently in the process of manufacturing a newly formulated therapy.
Metronidazole Delayed-Release Capsule
This is the product in the front of our pipeline for the treatment of CDI. It is developed based on Gateway Pharma’s patented technology of colon-specific delivery. Our goal is to develop a first-line medicine for treating the CDI and combat the AR threat to the US and world public health.
Other products in pipeline are currently under development and include using the same colon-specific delivery for therapeutics of CDI and other colon diseases, other gut infectious diseases and skin diseases.